REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Dec 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-12-11

Reporting Person: VAGELOS P ROY (Director, Chairman of the Board)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-11	Common Stock	M	153969	$21.92	Acquired	483512	Direct
2017-12-11	Common Stock	F	8805	$383.29	Disposed	474707	Direct
2017-12-11	Common Stock	F	74860	$383.29	Disposed	399847	Direct
2017-10-03	Common Stock	G	477	$0.0	Disposed	149808	Indirect
2017-11-07	Common Stock	G	91	$0.0	Disposed	149717	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-11	Non-Qualified Stock Option (right to buy)	$21.92	M	153969	Disposed	2017-12-17	Common Stock (153969)	Direct
2017-12-12	Non-Qualified Stock Option (right to buy)	$378.98	A	74390	Acquired	2027-12-12	Common Stock (74390)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2300	Indirect
Common Stock	83652	Indirect
Common Stock	1203	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.

F3: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F4: The stock option award vests in four equal annual installments, commencing one year after the date of grant.